# ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients

> **NCT01086501** · — · COMPLETED · sponsor: **Desitin Arzneimittel GmbH** · enrollment: 225 (actual)

## Conditions studied

- Epilepsy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01086501
- **Lead sponsor:** Desitin Arzneimittel GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-07
- **Final completion:** 2012-10
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2013-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01086501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01086501, "ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01086501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*